Assessment of Carfilzomib Treatment Response in Lung Transplant Recipients With Antibody-mediated Rejection

Assessment of Carfilzomib Treatment Response in Lung Transplant Recipients With Antibody-mediated Rejection

Background. Data supporting the use of carfilzomib (CFZ) for treatment of antibody-mediated rejection (AMR) in lung transplantation in combination with plasmapheresis and intravenous immunoglobulin suggest positive outcomes through donor-specific antibody (DSA) depletion or conversion to noncompleme...

Full description

Bibliographic Details
Main Authors: Christine Pham, PharmD, Brett J. Pierce, PharmD, Duc T. Nguyen, MD, PhD, Edward A. Graviss, PhD, MPH, Howard J. Huang, MD
Format: Article
Language:English
Published: Wolters Kluwer 2021-04-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001131

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001131

Similar Items